Allogene Therapeutics announces preliminary Phase 1 RESOLUTION trial data for ALLO-329 at ACR

Allogene Therapeutics announced preliminary safety, efficacy and translational data from its Phase 1 RESOLUTION trial of ALLO-329, presented at the American College of Rheumatology meeting.

Detected & updated continuously · Source: Nebula